Use of short-chain fatty acids in cancer prevention
Patent Information
- Application Number
- JP2023528582
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-12
- Filing Date
- 2021-11-12
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Chronic hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC), and existing treatments are inadequate, with a low survival rate and limited effective options.
Administering a pharmaceutical composition comprising therapeutically effective amounts of short-chain fatty acids (SCFAs) such as butyric acid and propionic acid, or their pharmaceutically acceptable salts, along with magnesium hydroxide, to treat hepatocellular carcinoma, targeting the HBV-encoded oncoprotein HBx and its associated signaling pathways.
The SCFA composition effectively blocks the progression from chronic liver disease to HCC by inhibiting HBx-induced carcinogenic pathways, reducing tumor development and size, and promoting apoptosis in cancer cells while sparing normal hepatocytes.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Technical Field
[0001] Cross - Reference to Related Applications This application claims the benefit of U.S. Provisional Application No. 63 / 112,783, filed on November 12, 2020, which is incorporated herein by reference in its entirety.
Background Art
[0002] Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The oncoprotein HBx encoded by HBV alters the expression of host genes and the activity of multiple signaling pathways. Short - chain fatty acids (SCFAs), which have anti - inflammatory and anti - tumor properties, can block the progression from chronic liver disease (CLD) to HCC.
[0003] Incorporation by Reference Each patent, publication, and non - patent literature cited in this application is incorporated herein by reference in its entirety, as if each were individually incorporated by reference.
Summary of the Invention
[0004] In some embodiments, a method of treating hepatocellular carcinoma, comprising administering a pharmaceutical composition to a subject having a need for treatment of hepatocellular carcinoma, the pharmaceutical composition comprising a first compound that is a therapeutically effective amount of a first short - chain fatty acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of a second short - chain fatty acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, is disclosed herein.
[0005] In some embodiments, a pharmaceutical composition comprising a first compound that is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, is disclosed herein.
[0006] In some embodiments, pharmaceutical compositions are disclosed herein that essentially consist of a first compound that is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide. [Brief explanation of the drawing]
[0007] [Figure 1] This specification outlines the experimental steps for the HBx transgenic (HBxTg) mouse study described herein.
[0008] [Figure 2] Panel A shows the percentage of tumor nodules from groups of 12-month-old mice treated with SCFA or PBS, relative to tumor size. Panel B shows examples of large tumors from PBS-treated mice. Panel C shows examples of two small tumors from SCFA-treated mice.
[0009] [Figure 3] This shows the number of mice with liver pathologies evaluated at 9 months (Panels A and B) and 12 months (Panels C and D).
[0010] [Figure 4] This study demonstrates the effects of SCFA on primary human hepatocytes and two HBx-expressing human HCC cell lines.
[0011] [Figure 5] Gene Ontology (GO) shows the number of proteins whose expression was decreased or increased in the liver of 12-month-old HBxTg mice treated with SCFA, compared to a PBS control, arranged by a biological process.
[0012] [Figure 6-1]The panels show immunohistochemical staining of HBx (panels A and D), Dab2 (panels B and E), normal IgG (panel C), or rabbit preimmune serum (panel F) in the livers of 12-month-old mice treated with PBS (panels A-C) or SCFA (panels D-F). Panel G shows representative Western blots of Dab2 and Shoc2 from treated (T) livers compared to control (C) livers. Panel H shows a summary of differentially expressed Dab2 and Shoc2 from treated (n=12) mice compared to control (n=12) mice (*P<0.01). Panel I shows a summary of proteomics data of SCFA against Ras-related proteins in the livers of 12-month-old HBxTg mice. [Figure 6-2] The panels show immunohistochemical staining of HBx (panels A and D), Dab2 (panels B and E), normal IgG (panel C), or rabbit preimmune serum (panel F) in the livers of 12-month-old mice treated with PBS (panels A-C) or SCFA (panels D-F). Panel G shows representative Western blots of Dab2 and Shoc2 from treated (T) livers compared to control (C) livers. Panel H shows a summary of differentially expressed Dab2 and Shoc2 from treated (n=12) mice compared to control (n=12) mice (*P<0.01). Panel I shows a summary of proteomics data of SCFA against Ras-related proteins in the livers of 12-month-old HBxTg mice.
[0013] [Figure 7] Panel A shows the pull-down assay for activated Ras in three different mice treated with PBS as a control (C), and in three mice treated with the test compound (T) and SCFA, prior to analysis. Panel B shows a summary of the Ras pull-down in seven mice treated with PBS compared with seven other mice treated with SCFA (*P<0.001).
[0014] [Figure 8]This report outlines the pathway analysis of SCFA-treated versus control HBx-Tg livers in 12-month-old animals. The pathways shown were consistently upregulated by HBx and downregulated by SCFA. [Modes for carrying out the invention]
[0015] Liver cancer is the sixth most commonly diagnosed and second most deadly cancer worldwide. Hepatitis cava (HCC) accounts for approximately 80% of primary liver cancer diagnoses globally. The incidence of HCC continues to rise, tripling in the United States over the past 20 years. Chronic HBV infection is a major risk factor for HCC. HBV infects approximately 2 billion people worldwide, of whom an estimated 250 million are carriers at high risk of developing hepatitis, cirrhosis, and HCC. In the United States, the two-year survival rate from diagnosis is less than 50%, and the five-year survival rate is only 8.9%, highlighting the urgent need for more effective treatment options.
[0016] Chronic infection with hepatitis B virus (HBV) is a major risk factor for the development of hepatocellular carcinoma (HCC). The HBV-encoded oncoprotein HBx alters the expression of host genes and the activity of multiple signaling pathways. HBx, encoded by HBV, may play a central role in the development of HCC.
[0017] The repetitive cycles of cell death and regeneration in CLD are associated with an increase in the integration of the HBx gene into the host DNA and the production of functional HBx, thereby leading to changes in host gene expression, chromosomal instability, and changes in signaling pathways important for cell survival, inflammation, angiogenesis, and immune response. Among the signaling pathways altered by HBx, the PI3K, Ras, and NF-κB signaling pathways promote cell survival and proliferation. Aberrant activation of PI3K, PDGF, VEGF, Ras, and NF-κB by HBx can lead to the initiation and progression of HCC. HBx can also alter host gene expression through epigenetic regulation by stimulating histone deacetylase (HDAC) and DNA methyltransferase (DNMT), and HBx can silence tumor suppressor genes and activate host oncogenes to promote carcinogenesis.
[0018] Changes in HCC can alter the composition of the gut microbiota. This change may correspond to changes in the levels and ratios of pro-inflammatory and anti-inflammatory metabolites in the intestine. SCFAs are produced by the anaerobic fermentation of dietary fibers by gut microbes. SCFAs regulate cell growth and differentiation, prevent or reduce the likelihood of inflammation, inhibit cell proliferation, and induce apoptosis in cancer cells. SCFAs can counteract the effects of HBx on many of the same molecules and pathways utilized by HBx in carcinogenesis. For example, SCFAs can reduce cell proliferation by inhibiting histone deacetylase (HDACi), while HBx stimulates the activity of selected HDACs. Thus, SCFAs can reverse the epigenetic effect of HBx on chromatin structure. SCFAs inhibit pro-inflammatory NF-κB signaling, while HBx stimulates NF-κB and related inflammation. Specifically, the expression and activity of HBx increase in an oxidative environment characteristic of inflammation. Furthermore, the intensity and distribution of HBx expression in the liver correlate with the severity of CLD, suggesting that the chronic inflammatory environment enhances the action of HBx.
[0019] Using short-chain fatty acids (SCFAs) with anti-inflammatory and anti-tumor properties, the progression from chronic liver disease (CLD) to HCC can be blocked. A method for blocking the progression from CLD to HCC using a pharmaceutical composition containing SCFA is disclosed herein.
[0020] A method for treating hepatocellular carcinoma, comprising administering a pharmaceutical composition to a subject in need of treatment for hepatocellular carcinoma, the pharmaceutical composition comprising a first compound which is a therapeutically effective amount of a first short-chain fatty acid or a pharmaceutically acceptable salt thereof, a second compound which is a therapeutically effective amount of a second short-chain fatty acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, is disclosed herein. A pharmaceutical composition comprising a first compound which is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound which is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide is further disclosed herein. Also disclosed herein is a pharmaceutical composition consisting essentially of a first compound which is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound which is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide.
[0021] The compounds of the present disclosure SCFA is a saturated fatty acid consisting of one polar carboxylic acid moiety and a hydrophobic hydrocarbon chain. The present disclosure describes the use of SCFA, SCFA precursors, SCFA biosynthetic precursors, compounds containing SCFA moieties, SCFA derivatives, or pharmaceutically acceptable salts thereof.
[0022] In some embodiments, the compounds of the disclosure are formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, or isovaleric acid. In some embodiments, the compounds of the disclosure are formates, acetates, propionates, butyrates, isobutyrates, valerates, or isovalerates, or pharmaceutically acceptable salts thereof. In some embodiments, the compounds of the disclosure are sodium formate, sodium acetate, sodium propionate, sodium butyrate, sodium isobutyrate, sodium valerate, or sodium isovalerate. In some embodiments, the compounds of the disclosure are methoxyacetic acid, valproic acid, 3-methoxypropionic acid, ethoxyacetic acid, triptyline, or propionic acid esters. In some embodiments, the compounds of the disclosure are butyrates, N-acetylbutyrates, phenylbutyrates, isobutyrates, pivaloyloxymethylbutyrate, or monoacetone glucose-3-butyrate. In some embodiments, the compounds of the present disclosure are sodium butyrate, sodium N-acetylbutyrate, sodium phenylbutyrate, sodium isobutyrate, sodium pivaloyloxymethylbutyrate, or sodium monoacetone glucose-3-butyrate. [ka]
[0023] In some embodiments, the compounds of the Disclosure are pyruvate, octanoate, dodecanoate, (4R)-4-hydroxypentanoate, 2-ethylhydracrylicate, 2-hydroxy-3-methylpentanoate, 2-methylbuta-2-enoic acid, butanoic acid, methylbutyric acid, dimethylbutyric acid, pentadienoic acid, pentenoic acid, pivalic acid, or propic acid. In some embodiments, the compounds of the Disclosure are pyruvate, octanoate, dodecanoate, (4R)-4-hydroxypentanoate, 2-ethylhydracrylate, 2-hydroxy-3-methylpentanoate, 2-methylbuta-2-enoate, butanoate, methylbutyrate, dimethylbutyrate, pentadienoate, pentenoate, pivalate, or propinoate, or any pharmaceutically acceptable salt of any of the foregoing.
[0024] In some embodiments, the compounds of the Disclosure are SCFA precursors or derivatives thereof. In some embodiments, the compounds of the Disclosure are lactates, succinates, formates, 1,2-propenediol, tryptamine, indole, indole-3-acetate, or pharmaceutically acceptable salts thereof.
[0025] In some embodiments, the compound of the disclosure is butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of the disclosure is sodium butyrate. In some embodiments, the compound of the disclosure is propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of the disclosure is sodium propionate.
[0026] In some embodiments, the compounds of the Disclosure are SCFA biosynthesis precursors or derivatives thereof. In some embodiments, the compounds of the Disclosure are acetyl-CoA carboxylase inhibitors, adenosine monophosphate kinase (AMPK) activators, or vitamin D.
[0027] Pharmaceutically acceptable salts This disclosure provides pharmaceutically acceptable salts of any therapeutic compound described herein. In some embodiments, this disclosure provides pharmaceutically acceptable hydrates or solvates of the compounds described herein. In some embodiments, this disclosure provides base addition salts. The base added to the compound to form a base addition salt may be an organic base or an inorganic base. In some embodiments, the pharmaceutically acceptable salt is a metal salt. In some embodiments, the pharmaceutically acceptable salt is an ammonium salt.
[0028] Metal salts may arise from the addition of an inorganic base to the compounds of this disclosure. The inorganic base consists of a metal cation paired with a basic counterion, such as a hydroxide, carbonate, bicarbonate, or phosphate. The metal may be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
[0029] In some embodiments, the metal salt is a lithium salt, sodium salt, potassium salt, cesium salt, cerium salt, magnesium salt, manganese salt, iron salt, calcium salt, strontium salt, cobalt salt, titanium salt, aluminum salt, copper salt, cadmium salt, or zinc salt.
[0030] Ammonium salts may result from the addition of ammonia or an organic amine to the compounds of the present disclosure. In some embodiments, the organic amine is triethylamine, diisopropylamine, ethanolamine, diethanolamine, triethanolamine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, piperazole, imidazole, pyrazine, or piperazine.
[0031] In some embodiments, the ammonium salt is triethylamine salt, diisopropylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, morpholine salt, N-methylmorpholine salt, piperidine salt, N-methylpiperidine salt, N-ethylpiperidine salt, dibenzylamine salt, piperazine salt, pyridine salt, pyrazole salt, piperazole salt, imidazole salt, pyrazine salt, or piperazine salt.
[0032] In some embodiments, the salt is hydrochloride, hydrobromide, hydroiodide, nitrate, nitrite, sulfate, sulfite, phosphate, isonicotinate, lactate, salicylate, tartrate, ascorbate, gentisinate, gluconate, glucuronate, saccharinate, formate, benzoate, glutamate, pantothenate, acetate, propionate, butyrate, fumarate, succinate, methanesulfonate (mesylate), ethanesulfonate, benzenesulfonate, p-toluenesulfonate, citrate, oxalate, or maleate.
[0033] In some embodiments, the compounds of the disclosure are esters of carboxylic acids. In some embodiments, the compounds of the disclosure are esters of a carboxylic acid with a branched or unbranched alkyl alcohol having 1 to 6 carbon atoms. In some embodiments, the compounds of the disclosure may be ethyl esters, propyl esters, butyl esters, isopropyl esters, t-butyl esters, pentyl esters, or hexyl esters.
[0034] In some embodiments, the pharmaceutical compositions of the present disclosure contain butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions of the present disclosure contain sodium butyrate. In some embodiments, the pharmaceutical compositions of the present disclosure contain propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical compositions of the present disclosure contain sodium propionate.
[0035] Pharmaceutical compositions of the present disclosure This disclosure provides pharmaceutical compositions comprising at least one compound of this disclosure. Pharmaceutical compositions of this disclosure may be combinations of any compound described herein with other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. Pharmaceutical compositions facilitate the administration of compounds to organisms, e.g., subjects. Pharmaceutical compositions can be administered in therapeutically effective doses as pharmaceutical compositions by various forms and routes, including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ocular, subcutaneous, transdermal, nasal, vaginal, and topical administration.
[0036] The pharmaceutical composition may be administered topically, for example, by direct injection of the compound into an organ, optionally as a depot formulation, a sustained-release formulation, or an implant.
[0037] In some embodiments, the pharmaceutical compositions of the Disclosure are formulated for oral administration. In some embodiments, the pharmaceutical compositions can be formulated by combining the compounds of the Disclosure with pharmaceutically acceptable carriers or excipients. Such carriers may be used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions for oral ingestion by a subject. Non-limiting examples of solvents used in orally soluble formulations include water, ethanol, isopropyl alcohol, saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate-buffered saline (PBS), sodium phosphate buffer, 4-2-hydroxy-1-piperazine ethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), and sodium citrate saline buffer (SSC). Non-limiting examples of cosolvents used in orally soluble formulations include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.
[0038] In some embodiments, the pharmaceutical preparations of this disclosure may be formulated for intravenous administration. The pharmaceutical composition may be in a form suitable for parenteral injection, such as a sterile suspension, solution, or emulsion in an oily or aqueous vehicle, and may contain formulation agents such as suspending agents, stabilizers, and / or dispersants.
[0039] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compound in a water-soluble form. The suspension of the active compound can be prepared as an oily injection suspension. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. The suspension may also contain suitable stabilizers or agents to increase the solubility of the compound to enable the preparation of high-concentration solutions. Alternatively, the active ingredient may be in powder form for preparation using a suitable vehicle (e.g., sterile water free of pyrogens) before use.
[0040] The active compounds can be administered topically and can be formulated into various topically administered compositions such as solutions, suspensions, lotions, gels, pastes, medicinal sticks, balms, creams, and ointments. Such pharmaceutical compositions may contain solubilizers, stabilizers, tonicity enhancers, buffers, and preservatives. The compounds of this disclosure can be applied topically to the skin or body cavities of a target, such as the oral cavity, vaginal cavity, bladder cavity, cranial cavity, spinal cavity, thoracic cavity, or pelvic cavity. The compounds of this disclosure can be applied to any available body cavities.
[0041] Pharmaceutical compositions may be formulated using one or more physiologically acceptable carriers, including excipients and adjuvants, that facilitate the processing of the active compound into a pharmaceutically usable preparation. The formulations may be modified depending on the selected route of administration. Pharmaceutical compositions containing the compounds described herein may be produced, for example, by mixing, dissolution, emulsification, encapsulation, encapsulation, or compression processes.
[0042] A pharmaceutical composition may contain at least one pharmaceutically acceptable carrier, diluent, or excipient, and a compound described herein in the form of a free base or a pharmaceutically acceptable salt. A pharmaceutical composition may also contain solubilizers, stabilizers, tonicity enhancers, buffers, and preservatives.
[0043] Methods for preparing compositions containing the compounds described herein include formulating the compounds with one or more inert, pharmaceutically acceptable excipients or carriers to form solid, semi-solid, or liquid compositions. Examples of solid compositions include powders, tablets, dispersible granules, capsules, and cachets. Examples of liquid compositions include solutions in which the compounds are dissolved, emulsions containing the compounds, or solutions containing liposomes, micelles, or nanoparticles containing the compounds disclosed herein. Examples of semi-solid compositions include gels, suspensions, and creams. The compositions may be liquid solutions or suspensions, solid forms suitable for dissolving or suspending in liquid before use, or emulsions. These compositions may also contain small amounts of non-toxic auxiliary substances, such as wetting agents or emulsifiers, pH buffers, and other pharmaceutically acceptable additives.
[0044] Non-limiting examples of dosage forms suitable for use in this disclosure include liquids, powders, gels, nanosuspensions, nanoparticles, microgels, aqueous or oily suspensions, emulsions, and any combination thereof.
[0045] Non-limiting examples of pharmaceutically acceptable excipients suitable for use in this disclosure include binders, disintegrants, anti-adhesives, antistatic agents, surfactants, antioxidants, coating agents, colorants, plasticizers, preservatives, suspending agents, emulsifiers, antimicrobial agents, spheroidizing agents, and any combination thereof. In some embodiments, the pharmaceutically acceptable excipients of this disclosure are pharmaceutical-grade excipients.
[0046] Pharmaceutical compositions may be provided in the form of rapid-release formulations, sustained-release formulations, or intermediate-release formulations. Rapid-release formulations may provide immediate release. Sustained-release formulations may provide controlled release or sustained delayed release. Pharmaceutical compositions of this disclosure may be, for example, immediate-release formulations or controlled-release formulations. Immediate-release formulations may be formulated to allow the compound to act rapidly. Non-limiting examples of immediate-release formulations include readily soluble formulations. Controlled-release formulations may be pharmaceutical formulations formulated to allow the release rate and release profile of the activator to meet physiological and chronotherapy requirements, or to result in the release of the activator at a programmed rate. Non-limiting examples of controlled-release formulations include granules, delayed-release granules, hydrogels (e.g., synthetic or naturally occurring), other gelling agents (e.g., gel-forming dietary fiber), matrix-based formulations (e.g., formulations comprising a polymer material in which at least one active ingredient is dispersed), granules in a matrix, polymer mixtures, and granular masses.
[0047] In some embodiments, the controlled-release formulation is a delayed-release form. The delayed-release form can be formulated to delay the action of the compound for an extended period. The delayed-release form can be formulated to delay the release of one or more compounds in an effective dose for, for example, about 4 hours, about 8 hours, about 12 hours, about 16 hours, or about 24 hours.
[0048] Controlled-release formulations may be sustained-release formulations. Sustained-release formulations can be formulated, for example, to sustain the action of a compound over a long period of time. Sustained-release formulations can be formulated to provide an effective dose of any compound described herein (for example, to provide a physiologically effective blood profile) over approximately 4 hours, approximately 8 hours, approximately 12 hours, approximately 16 hours, or approximately 24 hours.
[0049] Enteric coatings are polymer barriers applied to oral medications to prevent dissolution or disintegration in the gastric environment. Enteric coatings can protect drugs from gastric acidity, protect the stomach from the harmful effects of drugs, or release drugs after gastric dissolution. In some embodiments, the pharmaceutical compositions of the Disclosure are provided using enteric coatings. In some embodiments, the enteric coatings of the Disclosure are pharmaceutical-grade enteric coatings. In some embodiments, the pharmaceutical compositions of the Disclosure are provided using enteric coatings that dissolve in the lower gastrointestinal tract.
[0050] In some embodiments, the material used to provide an enteric coating to the compounds of the Disclosure is a fatty acid, wax, shellac, plastic, plant fiber, or film resin. In some embodiments, the enteric coating material is methyl acrylate-methacrylate copolymer, acetate phthalate cellulose (CAP), acetate succinate cellulose, hydroxypropyl methylcellulose phthalate, acetate succinate hydroxypropyl methylcellulose, acetate succinate hypromellose, polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylate copolymer, shellac, acetate trimellitate cellulose, sodium alginate, or zein. In some embodiments, the compound is provided as an enteric coating soft gel, and the enteric coating is provided as an enteric coating aqueous solution. In some embodiments, the enteric coating aqueous solution is ethyl cellulose, medium-chain triglycerides, oleic acid, sodium alginate, or stearic acid.
[0051] In some embodiments, the enteric coating is provided as Vcaps® enteric capsules. In some embodiments, the enteric coating is acetate phthalate cellulose, acetate trimellitate cellulose (CAT), polyvinyl acetate phthalate, phthalate hydroxypropyl methylcellulose, acetate succinate hydroxypropyl methylcellulose, poly(1:1 methacrylic acid:ethyl acrylate), poly(1:1 methacrylic acid:methyl methacrylate), or poly(1:2 methacrylic acid:methyl methacrylate). In some embodiments, the enteric coating is Eudragit® L30D, Eudragit® L100-55, HP-F, Sureteric®, Acryl-Eze®, Aquarius® Control ENA, Aquateric®, Aquacoat® ECD, or Aquasolve®.
[0052] Enteric coatings used to coat the pharmaceutical compositions of this disclosure may have a thickness of about 0.5 μm to about 500 μm. In some embodiments, the enteric coating may have a thickness of about 0.5 μm to about 5 μm, about 5 μm to about 20 μm, about 20 μm to about 50 μm, about 50 μm to about 100 μm, about 100 μm to about 200 μm, about 200 μm to about 300 μm, about 300 μm to about 400 μm, or about 400 μm to about 500 μm. In some embodiments, the enteric coating can have a thickness of approximately 0.5 μm, approximately 10 μm, approximately 25 μm, approximately 50 μm, approximately 75 μm, approximately 100 μm, approximately 150 μm, approximately 200 μm, approximately 250 μm, approximately 300 μm, approximately 350 μm, approximately 400 μm, approximately 450 μm, or approximately 500 μm. In some embodiments, the enteric coating has a thickness of approximately 200 μm. In some embodiments, the enteric coating has a thickness of approximately 350 μm. In some embodiments, the enteric coating has a thickness of approximately 500 μm.
[0053] Depending on the intended mode of administration, the pharmaceutical composition may be in the form of a solid, semi-solid, or liquid dosage form (e.g., tablets, suppositories, pills, capsules, powders, liquids, elixirs, suspensions, lotions, creams, or gels) (e.g., a unit dosage form suitable for a single dose of a precise dosage). In some embodiments, the pharmaceutical composition may be in the form of a nanosuspension, aqueous suspension, or oily suspension. In some embodiments, the pharmaceutical composition of the Disclosure may be in the form of a drop or syrup.
[0054] Examples of non-toxic solid carriers for the solid composition include pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate.
[0055] Non-limiting examples of pharmaceutically acceptable excipients suitable for use in this disclosure include granulators, binders, lubricants, disintegrants, sweeteners, flow enhancers, anti-adhesives, antistatic agents, surfactants, antioxidants, gums, coatings, colorants, flavorings, plasticizers, preservatives, suspending agents, emulsifiers, vegetable cellulosic materials and spheroidizers, and any combination thereof. In some embodiments, pharmaceutically acceptable excipients suitable for use in this disclosure may also include adjuvants, antioxidants, chelating agents, surfactants, foaming agents, wetting agents, emulsifiers, thickeners, buffering agents, or preservatives.
[0056] In some embodiments, the pharmaceutically acceptable excipient is a permeation enhancer. In some embodiments, the permeation enhancer is ethanol, glycerol monolaurate, polyethylene glycol monolaurate, or dimethyl sulfoxide. In some embodiments, the permeation enhancer is oleic acid, oleyl alcohol, ethoxydiglycol, laurocaprum, alkanecarboxylic acid, dimethyl sulfoxide, polar lipid, or N-methyl-2-pyrrolidone.
[0057] In some embodiments, the pharmaceutically acceptable excipient is a hydrotrope. In some embodiments, the hydrotrope is isopropyl alcohol, propylene glycol, or sodium xylene sulfonate.
[0058] In some embodiments, pharmaceutically acceptable excipients include tablet binders, tablet disintegrants, thickeners, tablet or capsule diluents, tablet or capsule disintegrants, heat stabilizers, adsorbents, film-forming agents, granulators, coating agents, flavor fixatives, colorants, sweeteners, or isotonic agents.
[0059] In some embodiments, pharmaceutically acceptable excipients include gum arabic (acacia), alginates, alginic acid, aluminum acetate, benzyl alcohol, butylparaben, butylated hydroxytoluene, citric acid, calcium carbonate, candelilla wax, sodium croscarmellose, powdered sugar, colloidal silicon dioxide, cellulose, simple or anhydrous calcium phosphate, carnauba wax, corn starch, carboxymethylcellulose calcium, calcium stearate, calcium disodium EDTA, copolividone, hydrogenated castor oil, calcium hydrogen phosphate dihydrate, cetylpyridine chloride, cysteine HCl, crospovidone, dicalcium or tricalcium phosphate, monocalcium phosphate, disodium monohydrogen phosphate, dimethicone, sodium erythrosine, ethylcellulose, gelatin, glyceryl monooleate, glycerin, glycine, glyceryl monostearate, glyceryl behenate, hydroxypropylcellulose, hydroxypropyl methylcellulose, hypromellose, HPMC phthalate, iron oxides, yellow iron oxides, red iron oxides Iron, lactose (hydrated or anhydrous), magnesium stearate, microcrystalline cellulose, mannitol, methylcellulose, magnesium carbonate, mineral oil, methacrylate copolymer, magnesium oxide, methylparaben, povidone (PVP), polyethylene glycol (PEG), polysorbate 80, propylene glycol, polyethylene oxide, propyleneparaben, polaxamer (407, 188, or plain), potassium bicarbonate, potassium sorbate, potato starch, phosphoric acid, polyoxy-140 stearate, sodium starch glycolate Lilium, alpha starch, sodium crosmellose, sodium lauryl sulfate, starch, silicon dioxide, sodium benzoate, stearic acid, sucrose, sorbic acid, sodium carbonate, sodium saccharin, sodium alginate, silica gel, sorbitan monooleate, sodium stearyl fumarate, sodium chloride, sodium metabisulfite, sodium citrate dihydrate, sodium starch, sodium carboxymethylcellulose, succinic acid, sodium propionate, titanium dioxide, talc,It is triacetin or triethyl citrate.
[0060] In some embodiments, the pharmaceutical compositions of the Disclosure may contain a stabilizer. In some embodiments, the pharmaceutical compositions of the Disclosure may contain magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure may contain up to about 3.0%, up to about 2.8%, up to about 2.6%, up to about 2.4%, up to about 2.2%, up to about 2.0%, up to about 1.8%, up to about 1.6%, up to about 1.4%, up to about 1.2%, up to about 1.0%, up to about 0.9%, up to about 0.8%, up to about 0.7%, up to about 0.6%, up to about 0.5%, up to about 0.4%, up to about 0.3%, up to about 0.2%, or up to about 0.1% (w / w) of magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure may contain up to about 3.0% (w / w) of magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure contain up to about 2.0% (w / w) magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure contain up to about 1.0% (w / w) magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure contain up to about 0.5% (w / w) magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure contain up to about 0.3% (w / w) magnesium hydroxide. In some embodiments, the pharmaceutical compositions of the Disclosure contain up to about 0.1% (w / w) magnesium hydroxide.
[0061] In some embodiments, the pharmaceutical composition of the present disclosure comprises butyric acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide. In some embodiments, the pharmaceutical composition of the present disclosure essentially consists of butyric acid or a pharmaceutically acceptable salt thereof, propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide.
[0062] Non-limiting examples of pharmaceutically acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, PA: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated as a whole by reference.
[0063] In carrying out the therapeutic methods or uses provided herein, a therapeutically effective amount of the compound described herein is administered in a pharmaceutical composition to a subject having the disease or condition to be treated. In some embodiments, the subject is a mammal such as a human. In some embodiments, the subject is an adult, an elderly adult, adolescent, pre-adolescent, child, infant, neonatal, or a non-human child, infant, neonatal, or non-human animal. In some embodiments, the subject is a patient.
[0064] Non-limiting examples of pharmaceutically active agents suitable for combination with the compositions of this disclosure include anti-infective agents, i.e., aminoglycosides, antiviral agents, antibacterial agents, anticholinergic / antispasmodic agents, antidiabetic agents, antihypertensive agents, antitumor agents, cardiovascular agents, central nervous system agents, coagulation regulators, hormones, immunologic agents, immunosuppressants, and ophthalmic preparations.
[0065] In some embodiments, the pharmaceutical composition of the present disclosure comprises a) a first short-chain fatty acid or a pharmaceutically acceptable salt thereof, and b) a second short-chain fatty acid or a pharmaceutically acceptable salt thereof, wherein the first short-chain fatty acid or a pharmaceutically acceptable salt and the second short-chain fatty acid or a pharmaceutically acceptable salt are present in the formulation in a ratio of at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least 11:1, at least 12:1, at least 13:1, at least 14:1, at least 15:1, at least 16:1, at least 17:1, at least 18:1, at least 19:1, or at least 20:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt and the second short-chain fatty acid or a pharmaceutically acceptable salt are present in the formulation in a ratio of at least 4:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof is present in the formulation in a ratio of at least 10:1 to the second short-chain fatty acid or a pharmaceutically acceptable salt thereof. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof is present in the formulation in a ratio of at least 15:1 to the second short-chain fatty acid or a pharmaceutically acceptable salt thereof.
[0066] In some embodiments, the pharmaceutical composition of the present disclosure comprises a) a first short-chain fatty acid or a pharmaceutically acceptable salt thereof, b) a second amino acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, wherein the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 2:1 to about 4:1, about 4:1 to about 6:1, about 6:1 to about 8:1, about 8:1 to about 10:1, about 10:1 to about 12:1, about 12:1 to about 14:1, about 14:1 to about 16:1, about 16:1 to about 18:1, or about 18:1 to about 20:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 14:1 to about 16:1.
[0067] In some embodiments, the pharmaceutical composition of the present disclosure comprises a) a first short-chain fatty acid or a pharmaceutically acceptable salt thereof, b) a second amino acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, wherein the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, or about 20:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 10:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of approximately 15:1.
[0068] In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof is butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof is sodium butyrate. In some embodiments, the first short-chain fatty acid is butyric acid. In some embodiments, the second short-chain fatty acid or a pharmaceutically acceptable salt thereof is propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the second short-chain fatty acid is sodium propionate. In some embodiments, the second short-chain fatty acid is propionic acid. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient is cellulose. In some embodiments, the pharmaceutically acceptable excipient is methylcellulose. In some embodiments, the pharmaceutically acceptable excipient is hydroxypropylcellulose. In some embodiments, the pharmaceutical composition further comprises an enteric coating. In some embodiments, the enteric coating is Vcaps® (hydroxypropylmethylcellulose) enteric capsules. In some embodiments, the enteric coating is CAT. In some embodiments, the pharmaceutical composition is formulated as a tablet. In some embodiments, the pharmaceutical composition is formulated as a capsule.
[0069] In some embodiments, the pharmaceutical composition of the present disclosure comprises a) butyric acid or a pharmaceutically acceptable salt thereof, b) propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, wherein the butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof are present in the pharmaceutical composition in a ratio of at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least 11:1, at least 12:1, at least 13:1, at least 14:1, at least 15:1, at least 16:1, at least 17:1, at least 18:1, at least 19:1, or at least 20:1. In some embodiments, the pharmaceutical composition of the present disclosure comprises a) sodium butyrate, b) sodium propionate, and magnesium hydroxide, wherein sodium butyrate and sodium propionate are present in the pharmaceutical composition in a ratio of at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1, at least 9:1, at least 10:1, at least 11:1, at least 12:1, at least 13:1, at least 14:1, at least 15:1, at least 16:1, at least 17:1, at least 18:1, at least 19:1, or at least 20:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of at least 4:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of at least 10:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of at least 15:1.
[0070] In some embodiments, the pharmaceutical composition of the present disclosure comprises a) butyric acid or a pharmaceutically acceptable salt thereof, b) propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide, wherein the butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof are present in the pharmaceutical composition in a ratio of about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, or about 20:1. In some embodiments, the pharmaceutical compositions of the present disclosure comprise sodium butyrate, sodium propionate, and magnesium hydroxide, wherein sodium butyrate and sodium propionate are present in the pharmaceutical composition in a ratio of about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, or about 20:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 4:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of about 10:1. In some embodiments, the first short-chain fatty acid or a pharmaceutically acceptable salt thereof and the second short-chain fatty acid or a pharmaceutically acceptable salt thereof are present in the formulation in a ratio of approximately 15:1.
[0071] In some embodiments, the first short-chain fatty acid is butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the first short-chain fatty acid is butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the first short-chain fatty acid is sodium butyrate. In some embodiments, the second short-chain fatty acid is propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the second short-chain fatty acid is propionic acid. In some embodiments, the second short-chain fatty acid is sodium propionate. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutically acceptable excipient is cellulose. In some embodiments, the pharmaceutically acceptable excipient is methylcellulose. In some embodiments, the pharmaceutically acceptable excipient is hydroxypropylcellulose. In some embodiments, the pharmaceutical composition further comprises an enteric coating. In some embodiments, the enteric coating is Vcaps® (hydroxypropylmethylcellulose) enteric capsules. In some embodiments, the enteric coating is CAT. In some embodiments, the pharmaceutical composition is formulated as a tablet. In some embodiments, the pharmaceutical composition is formulated as a capsule.
[0072] dosage The pharmaceutical compositions described herein may be in unit dose forms suitable for single-dose administration of precise dosages. In unit dose forms, the formulation is divided into unit doses containing an appropriate amount of one or more pharmaceutical compositions or formulations. Unit doses may be in the form of packages containing separate amounts of pharmaceutical compositions or formulations.
[0073] In some embodiments, the pharmaceutical compositions or formulations of the Disclosure are provided as liquids in vials or ampoules. In some embodiments, the pharmaceutical compositions or formulations of the Disclosure are provided as aqueous suspensions packaged in single-dose, non-resealable containers. In some embodiments, the pharmaceutical compositions or formulations of the Disclosure are provided as aqueous suspensions packaged in multi-dose, resealable containers. Multi-dose, resealable containers can be used, for example, in combination with preservatives.
[0074] In some embodiments, the pharmaceutical composition or formulation of the Disclosure is provided as a powder in a single-dose container, for example, a sachet. In some embodiments, the pharmaceutical composition or formulation of the Disclosure is provided as a powder in a resealable container for multiple doses. In some embodiments, the pharmaceutical composition or formulation of the Disclosure is provided in the form of a tablet. In some embodiments, the pharmaceutical composition or formulation of the Disclosure is provided in the form of a capsule.
[0075] In some embodiments, the compounds described herein may be present in the composition in amounts ranging from about 50 mg to about 100 mg, about 100 mg to about 200 mg, about 200 mg to about 300 mg, about 300 mg to about 400 mg, or about 400 mg to about 500 mg. In some embodiments, the compounds described herein may be present in the composition in amounts ranging from about 500 mg to about 5,000 mg, about 1,000 mg to about 5,000 mg, about 1,500 mg to about 4,000 mg, about 2,000 mg to about 3,000 mg, or about 2,500 mg to about 3,000 mg. In some embodiments, the compounds described herein are present in amounts of approximately 1,000 mg to approximately 1,200 mg, approximately 1,200 mg to approximately 1,400 mg, approximately 1,400 mg to approximately 1,600 mg, approximately 1,600 mg to approximately 1,800 mg, approximately 1,800 mg to approximately 2,000 mg, approximately 2,000 mg to approximately 2,200 mg, approximately 2,200 mg to approximately 2,400 mg, approximately 2,400 mg to approximately 2,600 mg, approximately 2,600 mg to approximately 2,800 mg, and approximately 2,800 mg to approximately 3,0 It may be present in the composition in the range of 00 mg, approximately 3,000 mg to approximately 3,200 mg, approximately 3,200 mg to approximately 3,400 mg, approximately 3,400 mg to approximately 3,600 mg, approximately 3,600 mg to approximately 3,800 mg, approximately 3,800 mg to approximately 4,000 mg, approximately 4,000 mg to approximately 4,200 mg, approximately 4,200 mg to approximately 4,400 mg, approximately 4,400 mg to approximately 4,600 mg, approximately 4,600 mg to approximately 4,800 mg, or approximately 4,800 mg to approximately 5,000 mg.
[0076] In some embodiments, the compounds described herein may be present in the composition in amounts of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg. In some embodiments, the compounds described herein may be present in the composition in amounts of about 500 mg, about 750 mg, about 1,000 mg, about 1,250 mg, about 1,500 mg, about 1,750 mg, about 2,000 mg, about 2,250 mg, about 2,500 mg, about 3,000 mg, about 3,250 mg, about 3,500 mg, about 3,750 mg, about 4,000 mg, about 4,250 mg, about 4,500 mg, about 4,750 mg, or about 5,000 mg.
[0077] In some embodiments, the dose can be expressed in terms of the amount of drug divided by the mass of the subject, for example, in milligrams of drug per kilogram of body mass of the subject. In some embodiments, the compound is administered in amounts ranging from about 1 mg / kg to about 5 mg / kg, about 5 mg / kg to about 10 mg / kg, about 10 mg / kg to about 15 mg / kg, about 15 mg / kg to about 20 mg / kg, about 20 mg / kg to about 25 mg / kg, about 25 mg / kg to about 30 mg / kg, about 30 mg / kg to about 35 mg / kg, about 35 mg / kg to about 40 mg / kg, about 40 mg / kg to about 45 mg / kg, or about 45 mg / kg to about 50 mg / kg, about 50 mg / kg to about 55 mg / kg, about 55 mg / kg to about 60 mg / kg, about 60 mg / kg to about 65 mg / kg, about 65 mg / kg to about 70 mg / kg, or about 70 mg / kg to about 75 mg / kg. In some embodiments, the compound is administered in amounts of approximately 10 mg / kg, approximately 15 mg / kg, approximately 20 mg / kg, approximately 25 mg / kg, approximately 30 mg / kg, approximately 35 mg / kg, approximately 40 mg / kg, approximately 45 mg / kg, approximately 50 mg / kg, approximately 55 mg / kg, approximately 60 mg / kg, approximately 65 mg / kg, approximately 70 mg / kg, or approximately 75 mg / kg.
[0078] In some embodiments, the compound is administered in amounts of approximately 1 mg / kg, approximately 2 mg / kg, approximately 3 mg / kg, approximately 4 mg / kg, approximately 5 mg / kg, or approximately 6 mg / kg. In some embodiments, the compound is administered in amounts of approximately 4 mg / kg. In some embodiments, the compound is administered in amounts of approximately 5 mg / kg.
[0079] In some embodiments, the compound is administered in amounts of approximately 50 mg / kg, approximately 55 mg / kg, approximately 60 mg / kg, approximately 65 mg / kg, or approximately 70 mg / kg. In some embodiments, the compound is administered in amounts of approximately 65 mg / kg. In some embodiments, the compound is administered in amounts of approximately 70 mg / kg.
[0080] In some embodiments, the pharmaceutical composition comprises one, two, three, four, or five compounds of the Disclosure. In some embodiments, the pharmaceutical composition comprises one compound of the Disclosure. In some embodiments, the pharmaceutical composition comprises two compounds of the Disclosure. In some embodiments, the pharmaceutical composition comprises three compounds of the Disclosure.
[0081] In some embodiments, the pharmaceutical composition comprises a first compound of the Disclosure and a second compound of the Disclosure. In some embodiments, the pharmaceutical composition comprises about 50 mg to about 4000 mg of the first compound and about 50 mg to about 500 mg of the second compound. In some embodiments, the pharmaceutical composition comprises about 1500 mg to about 2000 mg of the first compound and about 150 mg to about 200 mg of the second compound. In some embodiments, the pharmaceutical composition comprises about 3000 mg to about 4000 mg of the first compound and about 200 mg to about 300 mg of the second compound. In some embodiments, the pharmaceutical composition comprises about 2000 mg to about 3000 mg of the first compound and about 300 mg to about 400 mg of the second compound.
[0082] In some embodiments, the pharmaceutical composition comprises a first compound in an amount of about 65 mg / kg to about 70 mg / kg and a second compound in an amount of about 1 mg / kg to about 5 mg / kg. In some embodiments, the pharmaceutical composition comprises a first compound in an amount of about 65 mg / kg and a second compound in an amount of about 4 mg / kg. In some embodiments, the pharmaceutical composition comprises a first compound in an amount of about 70 mg / kg and a second compound in an amount of about 5 mg / kg.
[0083] In some embodiments, the pharmaceutical composition comprises butyric acid or a pharmaceutically acceptable salt thereof and one additional SCFA. In some embodiments, the pharmaceutical composition comprises propionic acid or a pharmaceutically acceptable salt thereof and butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises isobutyric acid or a pharmaceutically acceptable salt thereof and butyric acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises butyric acid or a pharmaceutically acceptable salt thereof and valerate or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises butyric acid or a pharmaceutically acceptable salt thereof and isovalerate or a pharmaceutically acceptable salt thereof.
[0084] In some embodiments, the pharmaceutical composition comprises sodium butyrate and one additional SCFA. In some embodiments, the pharmaceutical composition comprises sodium propionate and sodium butyrate. In some embodiments, the pharmaceutical composition comprises sodium isobutyrate and sodium butyrate. In some embodiments, the pharmaceutical composition comprises sodium butyrate and sodium valerate. In some embodiments, the pharmaceutical composition comprises sodium butyrate and sodium isovalerate.
[0085] In some embodiments, the pharmaceutical composition comprises butyric acid and one additional SCFA. In some embodiments, the pharmaceutical composition comprises propionic acid and butyric acid. In some embodiments, the pharmaceutical composition comprises isobutyric acid and butyric acid. In some embodiments, the pharmaceutical composition comprises butyric acid and valeric acid. In some embodiments, the pharmaceutical composition comprises butyric acid and isovaleric acid.
[0086] In some embodiments, the pharmaceutical composition comprises isobutyric acid or a pharmaceutically acceptable salt thereof and one additional SCFA. In some embodiments, the pharmaceutical composition comprises isobutyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises isobutyric acid or a pharmaceutically acceptable salt thereof and valerate or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises isobutyric acid or a pharmaceutically acceptable salt thereof and isovalerate or a pharmaceutically acceptable salt thereof.
[0087] In some embodiments, the pharmaceutical composition comprises sodium isobutyrate and one additional SCFA. In some embodiments, the pharmaceutical composition comprises sodium isobutyrate and sodium butyrate. In some embodiments, the pharmaceutical composition comprises sodium isobutyrate and sodium valerate. In some embodiments, the pharmaceutical composition comprises sodium isobutyrate and sodium isovalerate.
[0088] In some embodiments, the pharmaceutical composition comprises isobutyric acid and one additional SCFA. In some embodiments, the pharmaceutical composition comprises isobutyric acid and propionic acid. In some embodiments, the pharmaceutical composition comprises isobutyric acid and valeric acid. In some embodiments, the pharmaceutical composition comprises isobutyric acid and isovaleric acid.
[0089] In some embodiments, the pharmaceutical composition comprises about 1.5 g to about 2 g of butyric acid or a pharmaceutically acceptable salt thereof and about 150 mg to about 200 mg of propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 4 g of butyric acid or a pharmaceutically acceptable salt thereof and about 250 mg of propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 3.5 g to about 4 g of butyric acid or a pharmaceutically acceptable salt thereof and about 150 mg to about 300 mg of propionic acid or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition comprises about 2.5 g to about 3 g of butyric acid or a pharmaceutically acceptable salt thereof and about 300 mg to about 400 mg of propionic acid or a pharmaceutically acceptable salt thereof.
[0090] In some embodiments, the pharmaceutical composition comprises 250 mg of sodium propionate and 4,000 mg of sodium isobutyrate. In some embodiments, the pharmaceutical composition comprises 250 mg of sodium valerate and 4,000 mg of sodium isobutyrate. In some embodiments, the pharmaceutical composition comprises 250 mg of sodium isovalerate and 4,000 mg of sodium isobutyrate.
[0091] In some embodiments, the pharmaceutical composition comprises 250 mg of propionic acid and 4,000 mg of isobutyric acid. In some embodiments, the pharmaceutical composition comprises 250 mg of valeric acid and 4,000 mg of isobutyric acid. In some embodiments, the pharmaceutical composition comprises 250 mg of isovaleric acid and 4,000 mg of isobutyric acid.
[0092] Method of administration The pharmaceutical compositions or therapeutic agents described herein can be administered before, during, or after the onset of a disease or condition, and the timing of administration of the composition containing the therapeutic agent may vary. For example, the pharmaceutical compositions or therapeutic agents can be used as prophylactic agents and can be administered continuously to subjects susceptible to a condition or disease to reduce the likelihood of the disease or condition developing. The pharmaceutical compositions or therapeutic agents can be administered to subjects as soon as possible during or after the onset of symptoms. Administration of the pharmaceutical compositions or therapeutic agents can be initiated within the first 48 hours of symptom onset, within the first 24 hours of symptom onset, within the first 6 hours of symptom onset, or within 3 hours of symptom onset. The initial administration can be via any practical route, such as using any formulation described herein and via any route described herein.
[0093] In some embodiments, the pharmaceutical composition or therapeutic agent can be administered to a patient exhibiting initial symptoms of a disease. In some embodiments, the symptom is a cough. In some embodiments, the symptom is a fever. The pharmaceutical composition or therapeutic agent can be administered as soon as practically feasible after the onset of the disease or condition is detected or suspected, for a period of time necessary for the treatment of the disease, for example, about one to three months. In some embodiments, the length of time over which the pharmaceutical composition or therapeutic agent can be administered is about one day, about two days, about three days, about four days, about five days, about six days, about one week, about two weeks, about three weeks, about four weeks, about one month, about five weeks, about six weeks, about seven weeks, about eight weeks, about two months, about nine weeks, about ten weeks, about eleven weeks, about twelve weeks, about three months, about thirteen weeks, about fourteen weeks, about fifteen weeks, about sixteen weeks, about four months, about seventeen weeks, about eighteen weeks, about nineteen weeks, and about twenty weeks. The duration of treatment may be approximately 5 months, 21 weeks, 22 weeks, 23 weeks, 24 weeks, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 2.5 years, 3 years, 3.5 years, 4 years, 4.5 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. The length of treatment may vary for each individual.
[0094] Multiple pharmaceutical compositions or therapeutic agents can be administered in any order or simultaneously. In some embodiments, the pharmaceutical compositions of this disclosure are administered before or after treatment with another therapeutic agent. When administered simultaneously, the pharmaceutical compositions or therapeutic agents can be provided in a single unified form or in multiple forms, for example, as multiple separate pills. The pharmaceutical compositions or therapeutic agents can be packaged together or separately in a single package or in multiple packages. One or more of the pharmaceutical compositions or therapeutic agents can be administered in multiple doses. When not administered simultaneously, the timing between doses can vary up to about one month.
[0095] In some embodiments, the pharmaceutical composition is administered in a daily oral dose. In some embodiments, the pharmaceutical composition is administered in a daily oral dose three times a day. In some embodiments, the formulation is administered in a daily oral dose three times a day for one week. In some embodiments, the formulation is administered in a daily oral dose three times a day for two weeks. In some embodiments, the formulation is administered in a daily oral dose three times a day for three weeks.
[0096] In some embodiments, the pharmaceutical composition is administered in a daily oral dose with food. In some embodiments, the pharmaceutical composition is administered in a daily oral dose three times a day with each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for one week with each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for two weeks with each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for three weeks with each meal.
[0097] In some embodiments, the pharmaceutical composition is administered in a daily oral dose after meals. In some embodiments, the pharmaceutical composition is administered in a daily oral dose three times a day, after each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for one week, after each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for two weeks, after each meal. In some embodiments, the formulation is administered in a daily oral dose three times a day for three weeks, after each meal. In some embodiments, the formulation is administered approximately 5 minutes, 15 minutes, 30 minutes, or 1 hour after a meal.
[0098] In some embodiments, the pharmaceutical composition is administered in a daily oral dose. In some embodiments, the pharmaceutical composition is administered in a daily oral dose three times a day. In some embodiments, the formulation is administered in a daily oral dose three times a day for one month. In some embodiments, the formulation is administered in a daily oral dose three times a day for two months. In some embodiments, the formulation is administered in a daily oral dose three times a day for three months. In some embodiments, the formulation is administered in a daily oral dose three times a day for one year. In some embodiments, the formulation is administered in a daily oral dose three times a day for two years. In some embodiments, the formulation is administered in a daily oral dose three times a day for three years.
[0099] In some embodiments, the pharmaceutical composition is administered daily in an oral dose with food. In some embodiments, the pharmaceutical composition is administered daily in an oral dose three times a day with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for one month with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for two months with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for three months with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for one year with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for two years with each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for three years with each meal.
[0100] In some embodiments, the pharmaceutical composition is administered daily in an oral dose after meals. In some embodiments, the pharmaceutical composition is administered daily in an oral dose three times a day, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for one month, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for two months, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for three months, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for one year, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for two years, after each meal. In some embodiments, the formulation is administered daily in an oral dose three times a day for three years, after each meal. In some embodiments, the formulation is administered approximately 5 minutes, 15 minutes, 30 minutes, or 1 hour after a meal.
[0101] In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose three times a day. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose three times a day. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose three times a day for one week. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose three times a day for two weeks. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily oral dose three times a day for three weeks.
[0102] In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered daily orally with food. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered daily orally three times a day with each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered daily orally three times a day with each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered daily orally three times a day for one week with each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in daily oral doses three times a day for two weeks, with each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in daily oral doses three times a day for three weeks, with each meal.
[0103] In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally daily after meals. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally three times a day, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally three times a day, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally three times a day for one week, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally three times a day for two weeks, immediately after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered orally three times a day for three weeks, immediately after each meal. In some embodiments, the formulation is administered approximately 5 minutes, 15 minutes, 30 minutes, or 1 hour after a meal.
[0104] In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily oral doses. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in three oral doses per day. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily oral doses three times a day for one week. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily oral doses three times a day for two weeks. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily oral doses three times a day for three weeks.
[0105] In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered daily orally with meals. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered daily orally three times a day with each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered daily orally three times a day for one week with each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered daily orally three times a day for two weeks with each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered daily orally three times a day for three weeks with each meal.
[0106] In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered orally daily after meals. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered orally three times a day after each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered orally three times a day for one week after each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered orally three times a day for two weeks after each meal. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered orally three times a day for three weeks after each meal. In some embodiments, the formulation is administered approximately 5 minutes, 15 minutes, 30 minutes, or 1 hour after a meal.
[0107] In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily oral dose. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily oral dose three times a day. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily oral dose three times a day for one week. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily oral dose three times a day for two weeks. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily oral dose three times a day for three weeks.
[0108] In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered daily orally with meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered daily orally three times a day, each time with meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered daily orally three times a day, each time with meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered daily orally three times a day for one week, each time with meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered daily orally three times a day for two weeks, each time with meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or pharmaceutically acceptable salts thereof, is administered in daily oral doses three times a day for three weeks, with each meal.
[0109] In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered orally daily after meals. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered orally three times a day, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered orally three times a day, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered orally three times a day for one week, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered orally three times a day for two weeks, after each meal. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or pharmaceutically acceptable salts thereof, is administered in a daily oral dose three times a day after each meal for three weeks. In some embodiments, the formulation is administered approximately 5 minutes, 15 minutes, 30 minutes, or 1 hour after a meal.
[0110] In some embodiments, the pharmaceutical composition is administered in daily parenteral doses. In some embodiments, the pharmaceutical composition is administered in daily parenteral doses three times a day. In some embodiments, the formulation is administered in daily parenteral doses three times a day for one week. In some embodiments, the formulation is administered in daily parenteral doses three times a day for two weeks. In some embodiments, the formulation is administered in daily parenteral doses three times a day for three weeks.
[0111] In some embodiments, the pharmaceutical composition is administered in daily parenteral doses. In some embodiments, the pharmaceutical composition is administered in daily parenteral doses three times a day. In some embodiments, the formulation is administered in daily parenteral doses three times a day for one month. In some embodiments, the formulation is administered in daily parenteral doses three times a day for two months. In some embodiments, the formulation is administered in daily parenteral doses three times a day for three months. In some embodiments, the formulation is administered in daily parenteral doses three times a day for one year. In some embodiments, the formulation is administered in daily parenteral doses three times a day for two years. In some embodiments, the formulation is administered in daily parenteral doses three times a day for three years.
[0112] In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily parenteral dose. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered three times a day in a daily parenteral dose. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered three times a day for one week in a daily parenteral dose. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered three times a day for two weeks in a daily parenteral dose. In some embodiments, a pharmaceutical composition comprising butyric acid or a pharmaceutically acceptable salt thereof and propionic acid or a pharmaceutically acceptable salt thereof is administered in a daily parenteral dose three times a day for three weeks.
[0113] In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily parenteral doses. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily parenteral doses three times a day. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily parenteral doses three times a day for one week. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily parenteral doses three times a day for two weeks. In some embodiments, a pharmaceutical composition comprising sodium butyrate and sodium propionate is administered in daily parenteral doses three times a day for three weeks.
[0114] In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily parenteral dose. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily parenteral dose three times a day. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily parenteral dose three times a day for one week. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily parenteral dose three times a day for two weeks. In some embodiments, a pharmaceutical composition comprising butyric acid and propionic acid, or a pharmaceutically acceptable salt thereof, is administered in a daily parenteral dose three times a day for three weeks.
[0115] The pharmaceutical compositions described herein may be in unit dose forms suitable for single-dose administration of precise dosages. In unit dose forms, the formulation is divided into unit doses containing appropriate amounts of one or more compounds. Unit doses may be in the form of packages containing separate amounts of the formulation. Non-limiting examples include packaged injectables, vials, or ampoules. Aqueous suspension compositions may be packaged in single-dose, non-resealable containers. Multi-dose, resealable containers may be used, for example, with or without preservatives. Injectable formulations may be provided in unit dose forms, for example, in ampoules, or in multi-dose containers containing preservatives.
[0116] The pharmaceutical compositions of this disclosure can be used, for example, before, during, or after treatment of a subject with another pharmaceutical. In some embodiments, the pharmaceutical compositions of this disclosure are administered together with an antiviral agent. In some embodiments, the pharmaceutical compositions of this disclosure are administered together with an antibiotic. The pharmaceutical compositions provided herein can be administered in conjunction with other therapies, such as chemotherapy, radiation, surgery, anti-inflammatory agents, and selected vitamins. Other agents can be administered before, after, or concurrently with the pharmaceutical compositions.
[0117] The therapeutically effective dose can vary widely depending on the severity of the disease, the age and relative health status of the subject, the potency of the compound used, and other factors. The compound can be used alone or in combination with one or more therapeutic agents as a component of a mixture. In some embodiments, the compound can be used in combination with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 additional therapeutic agents. In some embodiments, the compound of the disclosure may be used with one additional therapeutic agent. In some embodiments, the compound of the disclosure may be used with two additional therapeutic agents. In some embodiments, the compound of the disclosure may be used with three additional therapeutic agents. In some embodiments, the pharmaceutical composition of the disclosure is administered together with an antiviral agent. In some embodiments, the pharmaceutical composition of the disclosure is administered together with an antibiotic.
[0118] Treatment method In some embodiments, the compositions of this disclosure can be used to treat a condition. In some embodiments, the condition is colitis-associated colorectal cancer (CRC). In some embodiments, the condition is hepatocellular carcinoma.
[0119] kit The compositions of this disclosure can be packaged as a kit. In some embodiments, the kit includes written instructions for the administration or use of the compositions. The instructions may be, for example, a label. The instructions may suggest conditional administration methods. The instructions provide the subject and supervising physician with the best guidance to achieve optimal clinical outcomes from the administration of the therapy. The instructions may be a label. In some embodiments, the label may be approved by a regulatory body, for example, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory body. [Examples]
[0120] Example 1: SCFA treatment reduces the number of dysplasia and HCC nodules. SCFA has been used to treat colitis-associated colorectal cancer that develops against a background of chronic inflammation, as well as HCC from CLD. Therefore, the experiment was designed to test the hypothesis that SCFA delays the development of dysplastic nodules and / or HCC in an HBx transgenic (HBxTg) mouse model that closely replicates many stages in the pathogenesis of CLD and HCC seen in human HBV carriers. To determine the effect of SCFA on the development of dysplastic nodules, HBxTg mice were treated with SCFA or PBS from 6–9 months of age (hereinafter referred to as the "9-month group"). To determine the effect of SCFA on the development of HCC, a further group of mice was treated with SCFA or PBS from 9–12 months of age (hereinafter referred to as the "12-month group").
[0121] At the end of treatment, livers from the 9-month and 12-month groups were evaluated histopathologically, and the livers of the 12-month group were further analyzed by proteomics (Figure 1). In both age groups, there was no statistically significant difference in the number of SCFA-treated mice that developed hepatitis or steatosis compared to PBS control mice (Tables 1 and 2). This result was expected, as the mice had developed these disease stages before the start of treatment. In contrast, a significantly lower number of SCFA-treated mice developed dysplasia in both the 9-month (P<0.02) and 12-month (P<0.05) groups.
[0122] Table 1 shows the liver histopathology of 9-month-old mice 3 months after treatment. Table 2 shows the liver histopathology of 12-month-old mice 3 months after treatment. The liver was evaluated for hepatitis, steatosis, dysplasia, and HCC in five different sections from different parts of each lobe. No HCC nodules were observed at this age. A plus sign (+) indicates the presence of a disease stage, and a minus sign (-) indicates its absence. The number of lesions was counted and listed in parentheses. [Table 1] [Table 2]
[0123] Furthermore, SCFA reduced the number of mice that developed HCC compared to the 12-month-old control group (Table 3, P<0.001). Table 3 shows tumors in SCFA-treated mice and control mice at 9 and 12 months of age. [Table 3] * P<0.02; ** P<0.001; *** P<0.05. PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0124] Among mice that developed tumors, SCFA-treated mice had predominantly smaller tumors compared to predominantly larger tumors in PBS-treated mice (Figure 2, P<0.001). Figure 2, Panel A shows the percentage of tumor nodules from groups of 12-month-old mice treated with SCFA or PBS, relative to tumor size. S: small tumors (<0.5 cm), M: medium-sized tumors (0.5–1 cm), L: large tumors (>1 cm). Panel B shows an example of a large tumor from PBS-treated mice. Panel C shows two examples of small tumors from SCFA-treated mice. Arrows in (B) and (C) indicate the location of the tumor nodules. PBS, phosphate-buffered saline; SCFA, short-chain fatty acids. Histopathological examination of liver sections from 9-month and 12-month-old mice using a light microscope revealed that HCC was present only in the livers of mice that also had other lesions characteristic of CLD, as well as in human carriers with HCC (Figure 3, Tables 1 and 2). Therefore, HCC is expressed in the background of CLD in both treated and control mice, but SCFA delays the pathogenesis of HBV-related HCC. Figure 3 shows the number of mice exhibiting pathology in the liver evaluated at 9 months (Panels A and B) and 12 months (Panels C and D). Comparisons are made between SCFA-treated mice (Panels A and C) and PBS-treated mice (Panels B and D) in each age group. HCC, hepatocellular carcinoma; PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0125] Example 2: SCFA specifically reduces cancer cell survival rate. Since SCFA was able to delay tumorigenesis in HBxTg mice, we designed additional experiments to evaluate whether SCFA affects the survival rate of human HCC. As previously described, when the Hep3Bx and Huh7x human hepatocellular carcinoma cell lines constitutively expressing HBx were treated with SCFA, cell viability decreased in a dose-dependent manner over 24 hours. In contrast, the survival rate of primary human hepatocytes was not affected by SCFA treatment at the same dose and duration (P<0.01; Figure 4). These observations are consistent with in vivo experiments and thereby demonstrate one way in which SCFA treatment partially inhibits tumor growth.
[0126] Figure 4 shows the effects of SCFA on primary human hepatocytes and two HBx-expressing human HCC cell lines. Primary human hepatocytes and HCC cell lines transfected with HBx (Hep3Bx and Huh7x) were treated with increasing concentrations of SCFA, and cell viability was evaluated using the MTS assay. Primary human hepatocytes (●), Huh7x [ka] and Hep3Bx [ka] All measurements were performed three times. The results are expressed as the survival rate (%) of SCFA-treated cells compared to PBS-treated cells. * This indicates p<0.01. SCFA stands for short-chain fatty acid.
[0127] Example 3: Differential protein expression by proteomics Mass spectrometry-based proteomics was performed on the livers of 12-month-old HBxTg mice treated with SCFA and control mice to determine the effects of SCFA on protein expression and signaling pathways in the biological processes at the age at which tumors appeared. Therefore, three biological replicas were included in each group analyzed. Tissue samples were taken from different lobes of the liver. While these may have contained microscopic tumors, the majority of cells in these samples were non-tumorous. Of the more than 3,000 proteins identified, 222 were differentially expressed in the 12-month group. Differentially expressed proteins include those detected in SCFA compared to the PBS-treated group at significantly different levels (P<0.05), as well as proteins detected in the majority or all samples in one group but not in any of the control group samples. The mass spectrometer used in this study, the Q exactive, is capable of detecting proteins present in samples as small as 1 ng, making it a highly sensitive mass spectrometer with a low detection limit.
[0128] Proteins differentially expressed in the livers of SCFA-treated mice compared to PBS-treated mice were positioned by their GO biological processes (Figure 5). Figure 5 shows the number of proteins whose expression was decreased (black bars) or increased (gray bars) in the livers of 12-month-old HBxTg mice after SCFA treatment, compared to PBS controls, as positioned by the GO biological processes. HBxTg, hepatitis B transgenic; PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0129] Of the 14 differentially expressed genes that mediate protein transport, 13 were detectable in control livers but below the detection limit in SCFA-treated samples. This observation suggests that SCFA downregulates protein transport, including the downregulation of proteins involved in Golgi-endosome transport (MON), exocytosis-regulating proteins (exocyst complex components 2 and 5), nuclear translocation and export-regulating proteins (importin-5, exportin-7, importin subunit α-1, nuclear pore complex protein Nup98), and proteins involved in NF-κB signaling (ELKS / Rab6 interaction CAST) family members (Table 4).
[0130] Table 4 shows the differentially expressed proteins in the liver of 12-month-old animals that are associated with biological processes altered by SCFA compared to PBS. [Table 4-1] [Table 4-2] * Monotransport follows the biological process. 1 + indicates a protein that is strongly upregulated by SCFA treatment and undetectable in PBS control. - indicates a protein that is strongly upregulated in PBS control and undetectable in SCFA-treated liver. Proteins with numerical values represent a multiplicative change in SCFA-treated mice compared to PBS-treated mice. PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0131] Furthermore, ten proteins involved in the apoptotic pathway were differentially expressed after SCFA treatment. This observation suggests that SCFA may promote apoptosis (via increased expression of STE20-like ser / thr kinase, ATP-dependent RNA helicase DDX47, and tumor suppressor DAB2) or protect against apoptosis (via upregulation of baculovirus IAP repeat-containing protein 6, downregulation of β-catenin-like protein 1, and tumor suppressor protein prune homolog). In transcriptional regulation, SCFA is a known transcription regulator via histone deacetylase inhibition, and treatment results in upregulated expression of transcription elongation factor A protein 3, ENY2, actin-like protein 6A, and leucine-rich repeat flightless interaction protein 1 (transcriptional repressor), as well as downregulated expression of β-arrestin-1, TGID subunit 5, and cryptochrome-1.
[0132] Transcription can also be altered by differential expression of the chromatin remodeling protein SWI / SNF complex subunits of SMARCC2 and nucleoplasmin-3. Expression of six mitochondrial proteins is also altered, detectable in PBS-controlled livers but undetectable in the livers of SCFA-treated mice. Expression of a smaller number of proteins is also altered by SCFA through various other pathways (Figure 5, Table 4).
[0133] Pathway analysis of 12-month-old livers showed that SCFA treatment was associated with downregulation of pathways known to be activated by HBx in hepatic carcinogenesis. These pathways included PI3K, PDGF, FGF, IGF, EGF, Wnt, VEGF, and Ras (Figure 5). Proteins associated with these pathways were upregulated in PBS-treated livers but undetectable in SCFA-treated livers. Abnormal activation of all these signaling pathways is involved in the onset and progression of HCC. These pathways promote cell proliferation and growth, block apoptosis, and promote angiogenesis, all of which influence the pathogenesis of HCC.
[0134] The results above showed that SCFA treatment was associated with reduced HCC nodule size and occurrence in some mice, as well as smaller tumors in others (Figure 2, Table 3). Since HBx is known to activate Ras in the pathogenesis of HCC, and many proteins involved in Ras signaling were altered by SCFA treatment in the livers of 12-month-old HBxTg mice (Figure 6), this pathway was selected for further analysis. Proteomic data revealed that several proteins directly related to Ras (e.g., the upstream Ras-Raf scaffold protein Shoc2, and the downstream activator MEK2) were decreased by SCFA treatment. Downstream Ras proteins, including CDK5 and p70S6k, were also decreased. The tumor suppressor and Ras inhibitor Dab2 was increased upon treatment (Table 4, Figure 6). Taken together, the proteomic results suggest that SCFA's ability to delay the development of neoplastic lesions is accompanied by downregulation of key pro-oncogenic proteins in the Ras pathway.
[0135] Example 4: Verification of differentially expressed RAS-related proteins The Ras / Raf / MEK / ERK signaling cascade drives cell proliferation, differentiation, apoptosis, and tumorigenesis, and is activated in 50–100% of human HCCs. HBx activates Ras by promoting the formation of the Shc-Grb2-Sos complex. Dab2 inhibits Ras activation by competitively blocking the formation of this complex. IHC was performed to validate the proteomics results for the Ras pathway. For HBx, many SCFA-treated and placebo-treated mice showed diffuse, lobular, and scattered histological staining in the nuclear and cytoplasmic compartments of cells, but the differences were not statistically significant. However, the intensity of HBx staining was reduced in SCFA-treated mice compared to controls (Figure 6, panels A and D, compare P<0.02). Cytoplasmic staining was observed in liver samples evaluated from all mice, although half of the animals also had nuclear HBx. When consecutive tissue slides from these same mice were stained for Dab2, scattered single cells showed weak cytoplasmic and sometimes nuclear staining for Dab2 in both SCFA-treated and placebo-treated mice, although these differences were not statistically significant. However, Dab2 staining was more extensive in numerous scattered cells, and lobular tissue staining was observed in SCFA-treated tissue compared to control tissue (Figure 6, panels B and E; compare P<0.025). Staining specificity was demonstrated using normal rabbit IgG (Figure 6, panel C) or an unrelated monoclonal antibody (Figure 6, panel F). Western blotting showed that Dab2 was upregulated 2.6 times in SCFA-treated mice compared to control mice, and the opposite was observed for Shoc2, which is required for Ras to activate Raf (Figure 6, panels G and H; P<0.01). Confirmation of Shoc2 and Dab2 changes detected by proteomics and Western blotting further supports the idea that SCFA can downregulate the Ras pathway.Furthermore, upregulation of Dab2, which suppresses Ras signaling, also resulted in suppression of downstream effectors such as MEK1 / 2, cyclin-dependent kinase 5 (CDK5), β-arrestin 1, and ribosomal kinase p70s6k, all of which were highly expressed in the liver of PBS-treated mice but undetectable in SCFA-treated mice by proteomic analysis (Figure 6, Panel I).
[0136] Figure 6 shows immunohistochemical staining of HBx (Panels A and D), Dab2 (Panels B and E), normal IgG (Panel C), or rabbit preimmune serum (Panel F) in the livers of 12-month-old mice treated with PBS (Panels A-C) or SCFA (Panels D-F). Panel G shows representative Western blots of Dab2 and Shoc2 from treated (T) livers compared to control (C) livers. Panel H shows a summary of differentially expressed Dab2 and Shoc2 from treated (n=12) mice compared to control (n=12) mice (*P<0.01). Panel I shows a summary of SCFA proteomics data for Ras-related proteins in the livers of 12-month-old HBxTg mice. Proteins whose expression increased with SCFA treatment are shown with triangles, and proteins whose expression decreased with SCFA treatment are shown with circles. Proteins in the Ras pathway that were not differentially expressed with SCFA treatment are shown with squares. Dab2, ineffective homolog 2; HBx, hepatitis B x; SV40, Simian virus 40; SCFA, short-chain fatty acid.
[0137] Ras is a small GTPase that circulates between an active GTP-bound form and an inactive GDP-bound form. We then designed experiments to determine the levels of active Ras (Ras-GTP) in 12-month-old SCFA-fed and PBS-fed livers using a GST pull-down assay. SCFA-treated HBxTg mouse livers showed a four-fold decrease in Ras-GTP expression compared to control samples (Figure 7), demonstrating that SCFA treatment was associated with a decrease in active Ras levels (P<0.001), as determined by proteomics (Table 4) and Western blotting (data not shown), but without change in total Ras protein levels. Given that Ras is known to stimulate many processes crucial to carcinogenesis and is activated in HCC, these results suggest that SCFA's ability to inhibit Ras contributes to the delayed pathogenesis of HCC in this animal model.
[0138] Panel A in Figure 7 shows the pull-down assay for activated Ras in three different mice treated with PBS as a control (C) and the test compound (T), and in three mice treated with SCFA, before analysis. Panel B shows an overview of the Ras pull-down in seven mice treated with PBS compared with seven other mice treated with SCFA. * P<0.001). Signal density was measured in arbitrary units (au). GTP, guanosine triphosphate; PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0139] Example 5: Discussion The experiment was designed to identify the changes occurring in the liver of HBxTg mice at the time of HCC nodule development. SCFA significantly reduced the number of mice that developed dysplasia by 9 months of age (Table 3). In 12-month-old mice, the treatment reduced the number of mice that developed both dysplasia and HCC (Table 3). Unexpectedly, the incidence of steatosis was higher in both treatment groups compared to controls, but these differences were not statistically significant. This may be due to higher fatty acid intake in the treatment groups, as previously reported. The 12-month group treated with SCFA had smaller tumors than control mice (Figure 2). This result suggests that SCFA treatment may either delay tumor development and / or directly affect the growth of established tumors. The latter was confirmed in vitro, where SCFA inhibited the growth of HBx-positive human HCC cell lines, Huh7x and Hep3Bx (Figure 4). These findings expand upon previous observations showing that butyrate inhibits the proliferation of HepG2.2.15 cells. Butyrate may also delay or prevent tumor progression by promoting differentiation of hepatocellular carcinoma cell lines. Treatment of primary human hepatocytes with SCFA did not result in any discernible loss of survival (Figure 4). This result suggests that the pathway affecting tumor cell survival was far more sensitive to SCFA than the same pathway in normal hepatocytes.
[0140] To distinguish the nature of these changes in signaling pathways and gene expression patterns underlying the effects of SCFA, proteomics were performed on multiple liver samples taken from 12-month-old mice. The results showed differential expression of many proteins in various biological processes (Figure 5), thereby highlighting the promising pleiotropic effect of SCFA on multi-stage carcinogenesis. Pathway analysis of these differentially expressed proteins in the liver revealed, among other things, suppressed Ras, PI3K, VEGF, TGF-β, interferon signaling, and inflammation-related pathways in response to SCFA treatment (Table 4). These same pathways are known to be activated by HBx (Figure 8).
[0141] Figure 8 shows an overview of the pathway analysis of SCFA-treated liver versus control HBxTg liver in 12-month-old animals. The pathways shown were consistently upregulated by HBx and downregulated by SCFA. EGF, epidermal growth factor, FGF, fibroblast growth factor; HBx, hepatitis B x; HBxTg, hepatitis B x transgenic; HCC, hepatocellular carcinoma; IGF, insulin-like growth factor; PDGF, platelet-derived growth factor; PI3K, phosphoinositide 3-kinase; SCFA, short-chain fatty acids; VEGF, vascular endothelial growth factor.
[0142] In addition, NF-κB, which is constitutively activated by HBx and plays a crucial role in the pathogenesis of HCC, is epigenetically downregulated by SCFAs, particularly butyrates. Among the downregulated cancer-related pathways described herein, Ras, PI3K, VEGF, FGF, and EGF are all activated by HBx in HCC and all crosstalk with NF-κB, suggesting that NF-κB inhibition may also occur. HBx protects infected cells from apoptosis by promoting the activity of the PI3K and Ras pathways. This deregulation has been found to promote HCC progression through unsuppressed cell proliferation, invasion, and metastasis. Alterations in other pathways, including angiogenesis (VEGF signaling), cell death (apoptotic signaling), immune-mediated disruption (T cell activity), sustained proliferation signaling (IGF, Ras, and PDGF), protumor-promoting inflammation (chemokine and cytokine signaling), and invasion and metastasis (integrin signaling), are all prominent cancer features that may underlie the multiple-stage delays that ultimately lead to the development of HCC, all of which are downregulated by SCFAs.
[0143] Previously, it was shown that HBx synergistically promotes the formation and progression of HCC in conjunction with Kras. This relationship also resulted in the deregulation of proteins, particularly Akt, TGF-β, and β-catenin. Proteomic analysis of HBV-infected tissue confirmed that HBx increases oxidative stress through interaction with HIF-1α, a pathway also demonstrated to be modified in the proteomic analysis described herein. Further analysis of HBV-HCC tissue compared to adjacent non-tumor tissue showed altered expression of β-catenin-related proteins, NF-κB signaling components, ribosomal subunits, ubiquitin-related proteins, respiratory complexes, and metabolism-related proteins, supporting the changes detected in this study. The data presented herein demonstrate that some of the proteins and pathways altered by HBx in the pathogenesis of HCC are reversed by treatment with SCFA.
[0144] Treatment with multi-kinase inhibitors, sorafenib, and related compounds has been the standard treatment for patients with advanced HCC. Specifically, the inhibition of the PI3K, PDGF, VEGF, IGF, TGF-β, and Ras pathways by sorafenib is widely considered to be the cause of the drug's chemotherapeutic effect. One problem that may limit the effectiveness of sorafenib is that it is offered to patients with advanced HCC, and earlier intervention may have prophylactic value when many of the significant changes leading to cancer have already occurred before tumor development. Since SCFA did not affect the survival rate of normal hepatocytes (Figure 4), SCFA is specifically toxic to malignant cells and may offer an alternative approach to limit toxicity among HBV carriers who already have significant liver damage.
[0145] Given that SCFA reduces the incidence of HCC in treated livers at 12 months of age, and that the Ras signaling pathway is stimulated by HBx and generally activated in HCC, further studies were conducted to investigate the activity and differential expression of Ras pathway components differentially expressed by proteomics. The results in Figure 6 show increased expression of the tumor suppressor Dab2 and decreased expression of Shoc2, a downstream Ras signaling pathway component. Ras activity was also significantly reduced by SCFA treatment (Figure 7). Importantly, epigenetic silencing of Dab2 in HCC is associated with Ras activation, thereby leading to the onset and progression of HCC. Since Dab2 negatively modulates Ras by competing for Sos binding to Grb2, thereby disrupting the formation of the Sos / Grb2 complex and suppressing the resulting Ras activation, this may be one mechanism by which SCFA delays the pathogenesis of HCC. Activation of this pathway has also been found in several other human cancers, including breast cancer, colon cancer, and prostate cancer, suggesting that SCFA may be beneficial in the treatment of other cancer types.
[0146] Epigenetic silencing of Dab2 has been investigated in other human cancers. Treatment with the well-known HDACi trichostatin A (TSA) restored Dab2 expression in nasopharyngeal cancer, squamous cell carcinoma, and transitional cell carcinoma cells. This result suggests that HDAC-mediated chromatin regulation may play a role in Dab2 downregulation. SCFAs can restore the expression of epigenetically silenced genes in several ways. Since butyrate has been shown to block HBx expression by inhibiting the HDAC, SIRT-1, SCFAs may block HBx itself, thereby preventing it from mediating its changes. Butyrate has also been shown to inhibit HBx expression in HepG2.2.15 cells, which was also observed in vivo. At the molecular level, SCFAs may inactivate HDACs by competitively binding to their active sites, thereby inhibiting tumor suppressor silencing. The reduction in HBx expression in the liver of SCFA-treated mice (Figure 6) may also restore the activity of the tumor suppressor p53, which is also known to be inhibited by HBx. Furthermore, Dab2 was identified as a target of miR-106b in cervical cancer. Dab2 suppression in HCC may be due to increased miR-106b expression promoted by HBx. Butyrate reduced miR-106b expression, which was accompanied by decreased cell proliferation. Therefore, targeting HBx function with the use of SCFA may provide a novel non-toxic approach for the treatment of HBV carriers with CLD at high risk of developing cirrhosis and HCC.
[0147] Example 6: Materials and Methods A. Short-chain fatty acids (SCFAs): SCFAs were purchased and used without further purification. The SCFAs were sodium salts of butyrate, propionate, and acetate.
[0148] B. Mice and Treatment: In HBxTg mice (C57B1 / 6×DBA), hepatitis and steatodystrophy develop in animals by 6 months of age, dysplasia by 9 months of age, and HCC nodules by 12 months of age. Siblings and littermates consisting of 6-month and 9-month-old mice of both sexes were treated with SCFA or phosphate-buffered saline (PBS) 5 days a week during the day via oral gastric tube feeding for 3 months. The SCFA concentrations were 40 mM butyrate, 67.5 mM acetate, and 25.9 mM propionate. Three months after treatment, the livers were removed and then examined histologically. Tumor diameters were measured using calipers for small nodules (<0.5 cm), medium nodules (0.5-1.0 cm), and large nodules (>1 cm). Liver samples from three 12-month-old mice were prepared for proteomics (see below).
[0149] The control group consisted of siblings and littermates. All mice were fed the same diet and given water at the discretion of the researchers. The mice were not fasted before treatment. Treatment was performed at approximately the same time each day during the light cycle. The mice were housed in autoclave cages equipped with Bed-o'cob® and a dome for enrichment. Three months after treatment, the mice were anesthetized with a ketamine / xylazine cocktail and then perfused with PBS.
[0150] Figure 1 shows an overview of the experimental steps in the HBx transgenic (HBxTg) mouse study. * The bar indicates the age in months of the mice at the time of euthanasia in each group. The bars indicate the treatment periods of 6–9 months (groups 1 and 2) and 9–12 months (groups 3 and 4) for mice treated with SCFA (groups 1 and 3) or PBS (groups 2 and 4). H&E, hematoxylin and eosin; IHC, immunohistochemistry; PBS, phosphate-buffered saline; SCFA, short-chain fatty acids.
[0151] C. Immunohistochemistry: Immunohistochemical (IHC) analysis was performed using paraffin-embedded sections of tissue samples. Primary antibodies were anti-HBx (anti-99), as well as rabbit polyclonal antibodies against Dab2 and Shoc2.
[0152] Liver tissue was excised from HBxTg mice, fixed in formalin, and embedded in paraffin. 5 μm thick tissue sections were prepared from these paraffin blocks. For immunohistochemistry (IHC), slides were deparaffinized, dehydrated, incubated in Unitrieve antigen recovery solution for 30 minutes, heated to 60°C, and stained using the UltraVision® detection system. Normal mouse immunoglobulin G (IgG) was used as a control against Dab2, while pre-collected rabbit serum from the same animals immunized to produce anti-99 antibody (anti-HBx peptide antibody) was used as a control for HBx IHC. For Dab2 staining, rabbit polyclonal antibody was used, with normal rabbit IgG as a control. Antibody dilutions were used as recommended by the manufacturer. IHC results were recorded as + (<20% positive cells), ++ (20-70% positive cells), and +++ (>70% positive cells). IHC was also evaluated at the cellular level as scattered (individual cells positive), lobular (groups of positive cells), or diffuse (most cells in the section positive). Subcellular localization of IHC was also evaluated as membrane (M), nucleus (N), or cytoplasm (C). Liver histopathology was evaluated using hematoxylin and eosin staining. Slides were independently evaluated by two researchers.
[0153] D. SDS / PAGES and Western Blotting Method: Protein lysates were prepared from rapidly frozen liver tissue samples derived from 12-month-old control and SCFA-treated HBxTg mouse livers. The pre-rapidly frozen liver tissue was homogenized in a lysis buffer containing a protease inhibitor cocktail. Cell debris was removed by two centrifugations at 14,000 g for 15 minutes each. Protein extracts from the cells were prepared using the same lysis buffer. For Western blotting (WB), 100 μg of protein extract from the liver tissue was separated by SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was incubated with anti-Dab2 or anti-Shoc2 and anti-β-actin. The blots were color-developed using the Odyssey® Western Blotting Kit. The secondary antibody used was IRDye® goat anti-mouse for β-actin detection, or goat anti-rabbit IgG for Dab2 or anti-Shoc2. Visualization was performed using the Odyssey® Fc imaging system, and quantification was performed using Image Studio® software.
[0154] E.RAS Activity Assay: Ras activation assays were performed on control and SCFA-treated HBxTg mouse liver samples according to the manufacturer's instructions to isolate GTP-bound Ras. After isolation, the samples were separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was incubated with anti-ras and IRDye® goat anti-rabbit IgG. The blots were color-developed using the Odyssey® Western Blotting Kit. The blots were visualized using the Odyssey® Fc Imaging System and quantified using Image Studio® software.
[0155] F. Cell Culture: Hu7 and Hep3B cells were stably transduced with the Hbx gene using recombinant retrovirus (referred to as Hu7x and Hep3Bx, respectively), and cultured without selecting individual clones as described above. Primary human hepatocytes were purchased from Zen-Bio, Inc. and cultured according to the manufacturer's instructions.
[0156] G. Cell viability and treatment: Cells were seeded in 96-well plates in complete DMEM and incubated overnight in 5% CO2. Treatment consisted of different concentrations of SCFA (0, 1, 5, and 10 mM) over 24 hours. Cell viability was then determined three times using the MTS assay according to the manufacturer's instructions.
[0157] H. Proteomics and Data Analysis: Liver tissue from 12-month-old control (n=3) and SCFA-treated (n=3) HBxTg mice was homogenized, and extracted proteins were digested. The peptides were acidified, loaded onto the tip of an activated in-house cation stage, purified, and eluted into three fractions. Mass spectrometry was performed on these fractions. Differentially modified proteins were organized into functional pathways using the PANTHER (protein analysis by evolutionary relationships) classification system.
[0158] The samples were centrifuged at 14,000 g for 10 minutes. After determining the protein concentration using the Bradford assay, 100 μg of protein was digested with trypsin. The samples were fractionated and desalted according to the in-StageTip treatment protocol.
[0159] Label-free proteome analysis was performed independently on these fractions from each mouse in each group. Peptide mixtures were fractionated by ion-exchange chromatography, identified by Q Exactive® mass spectrometry using MaxQuant® software, and further analyzed by PANTHER. Electrospray ionization (ESI) was performed using an emitter (ID 30 μM, length 40 mm) with a spray voltage of -1800 V. MS / MS fragmentation was performed on the 10 most abundant ions in each spectrum using collision-induced dissociation with dynamic exclusion (exclusion for 10.0 seconds after one spectrum) with automatic switching between MS mode and MS / MS mode. The peptide misidentification rate (FDR) was 0.01, the protein FDR was 0.01, the minimum peptide length was 7 amino acids, and the minimum laser and unique peptide was 1 minute. The generated peak list was processed using Andromeda® software and searched against the SwissProt mouse database (release January 2018; 16,950 sequences). Andromeda search parameters were set as: mouse (Mus musculus) (species); trypsin (enzyme); carbamide methyl on Cys (fixed modification); (variable modification), methionine oxidation and acetyl (protein N-terminus); 7 ppm mass tolerance for precursor peptides and 20 ppm mass tolerance for generated ions. Data were filtered using 1% protein and peptide spectral match (PSM) FDR.
[0160] I. Statistics: All data was analyzed using Excel® or GGraphPad® software, and further statistical analysis was performed as outlined below.
[0161] For proteomics, t-tests were performed for statistical significance on quantified proteins, specifically selected proteins with low variance within the group and proteins differentially expressed between groups. Differentially expressed proteins (size difference greater than 2 compared to control mice, P<0.05) were selected for PANTHER pathway analysis. Furthermore, proteins detected in the majority or all samples from one group but not in the comparison group samples were selected for pathway analysis and literature search.
[0162] Chi-square analysis was used to determine the significance of the percentage of treated versus control HBxTg mouse livers that developed dysplasia and HCC. Student's t-test was used to evaluate the significance of dysplastic nodule development in 9-month-old treated HBxTg mice versus control HBxTg mice, and tumor development in 12-month-old treated HBxTg mice versus control HBxTg mice. Differences in Dab2 staining intensity between treated and control mice were evaluated by chi-square analysis. Differences in cell viability in cell lines were determined by Student's t-test. A P<0.05 value was considered statistically significant.
[0163] Example 7: Treatment of HBx transgenic mice with a formulation containing butyrate, propionate, and magnesium hydroxide. HBx transgenic mice (C57B1 / 6×DBA) were created and modified so that the mice would develop hepatitis and steatodystrophy by 6 months of age, dysplasia by 9 months of age, and HCC nodules by 12 months of age. Siblings consisting of 6-month and 9-month-old mice of both sexes were treated with Formulation 1 (40 mM butyrate, 25.9 mM propionate, and 9 mM Mg(OH)2) or phosphate-buffered saline (PBS) during the day, 7 days a week. Formulation 1 or PBS was administered for 3 months by adding it to drinking water. The water was replaced daily with a fresh sample of Formulation 1 or PBS. Each group consisted of 10 mice, with approximately equal numbers of males and females.
[0164] Three months after treatment with formulation 1 (group 1) or placebo (group 2) from 6–9 months of age, or three months after treatment with formulation 1 (group 3) or placebo (group 4) from 9–12 months of age, mice are euthanized by blood loss, and their livers are removed for further analysis. For further experiments, mice are treated with formulation 1 (group 5) or PBS (group 6) for nine months (3–12 months of age). Blood samples are screened by flow cytometry for pro-inflammatory and anti-inflammatory markers, as well as the frequency of CD8+ T cells and FoxP3+ T cells. HBx expression is evaluated in the livers of mice treated with formulation 1 and PBS.
[0165] Example 8: Treatment of HBV-associated hepatitis with a formulation containing butyric acid, propionic acid, and magnesium hydroxide. A total of 100 patients with a median age of 60 will be recruited. Patients will have ongoing HBV infection and associated hepatitis and / or cirrhosis, and will not have contraindications to butyrate. Patients will be administered either a formulation containing 1 g sodium butyrate, 100 mg sodium propionate, and 0.0055 mg magnesium hydroxide three times daily, or a placebo, and will be included in a hepatocellular carcinoma (HCC) screening program. Participants will be followed for a median of 5 years. Immediately prior to treatment, patients will be screened for ALT / AST, GGT; liver stiffness by FibroScan; pro-inflammatory and anti-inflammatory cytokines in the blood (TNFα, IFNγ, IL-2, IL-4, IL5-IL10); and HBV markers (HBeAg, anti-HBe, and HBV DNA). Screening will be repeated annually until the trial is completed. We will analyze patients using multivariate analysis to examine the incidence of chronic liver disease (hepatitis and fibrosis), liver cancer, chronic liver disease-related death (usually due to cirrhosis), or transplantation in the treated and untreated cohorts.
[0166] Embodiment The following non-limiting embodiments provide exemplary examples of the present invention, but do not limit the scope of the invention.
[0167] Embodiment 1. A method for treating hepatocellular carcinoma, comprising administering a pharmaceutical composition to a subject in need of treatment for hepatocellular carcinoma, wherein the pharmaceutical composition comprises a first compound that is a therapeutically effective amount of a first short-chain fatty acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of a second short-chain fatty acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide.
[0168] Embodiment 2. The method according to Embodiment 1, wherein the hepatocellular carcinoma is hepatitis B virus-associated hepatocellular carcinoma.
[0169] Embodiment 3. The method according to Embodiment 1 or 2, wherein administration is by oral administration.
[0170] Embodiment 4. The method according to Embodiment 1 or 2, wherein administration is by subcutaneous administration.
[0171] Embodiment 5. The method according to Embodiment 1 or 2, wherein administration is by intravenous administration.
[0172] Embodiment 6. The method according to any one of Embodiments 1 to 5, wherein the first compound is butyric acid.
[0173] Embodiment 7. The method according to Embodiment 6, wherein the first compound is sodium butyrate.
[0174] Embodiment 8. The method according to Embodiment 1, wherein the therapeutically effective dose of the first compound is approximately 500 mg to approximately 4000 mg.
[0175] Embodiment 9. The method according to Embodiment 1, wherein the therapeutically effective dose of the first compound is approximately 2000 mg.
[0176] Embodiment 10. The method according to Embodiment 1, wherein the therapeutically effective dose of the first compound is approximately 3000 mg.
[0177] Embodiment 11. The method according to Embodiment 1, wherein the therapeutically effective dose of the first compound is approximately 4000 mg.
[0178] Embodiment 12. The method according to any one of Embodiments 1 to 11, wherein the second compound is propionic acid.
[0179] Embodiment 13. The method according to Embodiment 12, wherein the second compound is sodium butyrate.
[0180] Embodiment 14. The method according to any one of Embodiments 1 to 13, wherein the therapeutically effective dose of the second compound is about 50 mg to about 500 mg.
[0181] Embodiment 15. The method according to any one of Embodiments 1 to 13, wherein the therapeutically effective dose of the second compound is about 150 mg.
[0182] Embodiment 16. The method according to any one of Embodiments 1 to 13, wherein the therapeutically effective dose of the second compound is about 250 mg.
[0183] Embodiment 17. The method according to any one of Embodiments 1 to 13, wherein the therapeutically effective dose of the second compound is about 400 mg.
[0184] Embodiment 18. The method according to any one of Embodiments 1 to 17, wherein the pharmaceutical composition contains up to about 0.5% (w / w) magnesium hydroxide.
[0185] Embodiment 19. The method according to any one of Embodiments 1 to 17, wherein the pharmaceutical composition contains up to about 0.3% (w / w) magnesium hydroxide.
[0186] Embodiment 20. The method according to any one of Embodiments 1 to 17, wherein the pharmaceutical composition contains up to about 0.1% (w / w) magnesium hydroxide.
[0187] Embodiment 21. The method according to any one of Embodiments 1 to 20, wherein the pharmaceutical composition further comprises pharmaceutically acceptable excipients.
[0188] Embodiment 22. The method according to Embodiment 21, wherein the pharmaceutically acceptable excipient is cellulose.
[0189] Embodiment 23. The method according to Embodiment 21, wherein the pharmaceutically acceptable excipient is methylcellulose.
[0190] Embodiment 24. The method according to Embodiment 21, wherein the pharmaceutically acceptable excipient is hydroxypropyl methylcellulose.
[0191] Embodiment 25. The method according to any one of Embodiments 1 to 24, wherein the pharmaceutical composition further comprises an enteric coating.
[0192] Embodiment 26. The method according to Embodiment 25, wherein the enteric coating is a hydroxypropyl methylcellulose capsule.
[0193] Embodiment 27. The method according to any one of Embodiments 1 to 26, wherein the pharmaceutical composition is formulated as a tablet.
[0194] Embodiment 28. The method according to any one of Embodiments 1 to 26, wherein the pharmaceutical composition is formulated as a capsule.
[0195] Embodiment 29. The method according to any one of Embodiments 1 to 28, wherein the subject is a human.
[0196] Embodiment 30. A pharmaceutical composition comprising a first compound that is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide.
[0197] Embodiment 31. A pharmaceutical composition comprising essentially a first compound that is a therapeutically effective amount of butyric acid or a pharmaceutically acceptable salt thereof, a second compound that is a therapeutically effective amount of propionic acid or a pharmaceutically acceptable salt thereof, and magnesium hydroxide.
[0198] Embodiment 32. The pharmaceutical composition according to Embodiment 30 or 31, wherein the therapeutically effective dose of the first compound is about 500 mg to about 4000 mg.
[0199] Embodiment 33. The pharmaceutical composition according to Embodiment 30 or 31, wherein the therapeutically effective dose of the first compound is approximately 2000 mg.
[0200] Embodiment 34. The pharmaceutical composition according to Embodiment 30 or 31, wherein the therapeutically effective dose of the first compound is approximately 3000 mg.
[0201] Embodiment 35. The pharmaceutical composition according to Embodiment 30 or 31, wherein the therapeutically effective dose of the first compound is approximately 4000 mg.
[0202] Embodiment 36. The pharmaceutical composition according to Embodiment 30 or 31, wherein the pharmaceutically acceptable salt of the first compound is sodium butyrate.
[0203] Embodiment 37. A pharmaceutical composition according to any one of Embodiments 30 to 36, wherein the therapeutically effective dose of the second compound is about 50 mg to about 500 mg.
[0204] Embodiment 38. A pharmaceutical composition according to any one of Embodiments 30 to 36, wherein the therapeutically effective dose of the second compound is about 150 mg.
[0205] Embodiment 39. The pharmaceutical composition according to any one of Embodiments 30 to 36, wherein the therapeutically effective dose of the second compound is about 250 mg.
[0206] Embodiment 40. A pharmaceutical composition according to any one of Embodiments 30 to 36, wherein the therapeutically effective dose of the second compound is about 400 mg.
[0207] Embodiment 41. The pharmaceutical composition according to any one of Embodiments 30 to 40, wherein the pharmaceutically acceptable salt of the second compound is sodium propionate.
[0208] Embodiment 42. The pharmaceutical composition according to any one of Embodiments 30 to 41, wherein the pharmaceutical composition contains up to about 0.5% (w / w) magnesium hydroxide.
[0209] Embodiment 43. A pharmaceutical composition according to any one of Embodiments 30 to 41, wherein the pharmaceutical composition contains up to about 0.3% (w / w) magnesium hydroxide.
[0210] Embodiment 44. A pharmaceutical composition according to any one of Embodiments 30 to 41, wherein the pharmaceutical composition contains up to about 0.1% (w / w) of magnesium hydroxide.
[0211] Embodiment 45. A pharmaceutical composition according to any one of Embodiments 30 to 44, further comprising pharmaceutically acceptable excipients.
[0212] Embodiment 46. The pharmaceutical composition according to Embodiment 45, wherein the pharmaceutically acceptable excipient is cellulose.
[0213] Embodiment 47. The pharmaceutical composition according to Embodiment 45, wherein the pharmaceutically acceptable excipient is methylcellulose.
[0214] Embodiment 48. The pharmaceutical composition according to Embodiment 45, wherein the pharmaceutically acceptable excipient is hydroxypropyl methylcellulose.
[0215] Embodiment 49. The pharmaceutical composition according to any one of Embodiments 30 to 48, wherein the pharmaceutical composition further comprises an enteric coating.
[0216] Embodiment 50. The pharmaceutical composition according to Embodiment 49, wherein the enteric coating is a hydroxypropyl methylcellulose capsule.
[0217] Embodiment 51. The pharmaceutical composition according to any one of Embodiments 30 to 50, wherein the pharmaceutical composition is formulated as a tablet.
[0218] Embodiment 52. The pharmaceutical composition according to any one of Embodiments 30 to 50, wherein the pharmaceutical composition is formulated as a capsule.
Claims
1. A pharmaceutical composition for use in preventing or delaying the onset of a condition, the pharmaceutical composition comprising a therapeutically effective amount of at least one short chain fatty acid selected from the group consisting of acetic acid or a pharma-ceutical acceptable salt thereof, propionic acid or a pharma-ceutical acceptable salt thereof, and butyric acid or a pharma-ceutical acceptable salt thereof, wherein the condition is associated with abnormal activation of Ras / Raf / MEK / ERK signaling.
2. The pharmaceutical composition of claim 1 , wherein the condition is cancer.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is administered orally.
4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises butyric acid or a pharma- ceutically acceptable salt thereof.
5. 5. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount of the butyric acid or a pharma- ceutically acceptable salt thereof is from about 500 mg to about 4000 mg.
6. 5. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount of the butyric acid or a pharma- ceutically acceptable salt thereof is about 2000 mg.
7. 5. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount of the butyric acid or a pharma- ceutically acceptable salt thereof is about 3000 mg.
8. 5. The pharmaceutical composition of claim 4, wherein the therapeutically effective amount of the butyric acid or a pharma- ceutically acceptable salt thereof is about 4000 mg.
9. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises propionic acid or a pharma- ceutically acceptable salt thereof.
10. 2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of propionic acid or a pharma- ceutically acceptable salt thereof is from about 50 mg to about 500 mg.
11. 2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of propionic acid or a pharma- ceutically acceptable salt thereof is about 150 mg.
12. 2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of propionic acid or a pharma- ceutically acceptable salt thereof is about 250 mg.
13. The pharmaceutical composition of claim 1 , further comprising a pharma- ceutically acceptable excipient.
14. The pharmaceutical composition of claim 1 , further comprising an enteric coating.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a tablet or capsule.
16. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a therapeutically effective amount of acetic acid or a pharma- ceutically acceptable salt thereof.
17. The pharmaceutical composition of claim 1, wherein the condition is selected from the group consisting of liver cancer, colon cancer, breast cancer, and prostate cancer.
18. A pharmaceutical composition as described in claim 1 for use in the treatment of liver disease or liver inflammation.
19. The pharmaceutical composition of claim 1 for use in preventing tumor growth or delaying the onset of tumors.
20. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition downregulates one or more proteins associated with Ras / Raf / MEK / ERK signaling.
